GASTROINTESTINAL (GI) MEDICINES
WE AIM TO DEVELOP OUR LEADING POSITION IN GI TREATMENTS BY FOCUSING ON LIFE CYCLE INITIATIVES FOR NEXIUM TO GAIN FURTHER MARKET PENETRATION BY BROADENING ITS USE, COUPLED WITH INNOVATIVE RESEARCH AND DEVELOPMENT OF NEW THERAPIES FOR GASTRO-OESOPHAGEAL REFLUX DISEASE (GERD).
2007 IN BRIEF
- Sales of Nexium down 2% to $5.2 billion.
- Losec/Prilosec sales of over $1 billion with sales growth in Japan and China. Overall sales down 20%.
- European Patent Office rulings that the European process patent for Nexium and the European patent for the Multiple Unit Pellet (MUPS) formulations of Losec and Nexium, which expire in 2015, are valid in amended form.
- Patent litigation continuing in the US against generic manufacturers following abbreviated new drug applications relating to Nexium.
MARKETED PRODUCTS
Nexium (esomeprazole) is the first proton pump inhibitor (PPI) for the treatment of acid-related diseases to offer clinical improvements over other PPIs and other treatments.
Losec/Prilosec (omeprazole) was the first PPI, and is used for the short-term and long-term treatment of acid-related diseases.
Entocort (budesonide) is a locally acting corticosteroid for the treatment of inflammatory bowel disease (IBD) with better tolerability than other corticosteroids and greater efficacy than aminosalicylic acid medicines.
